I am wondering if I still need to be overly concerned about my A1C reading. — A. ANSWER: Although there are no clear studies ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

During the trial, the pill lowered patients' A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, according to Lilly.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.